Amyotrophic Lateral Sclerosis Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Amyotrophic Lateral Sclerosis remains an active clinical development field. The field is increasingly separating symptomatic benefit from disease modification, while enrichment, digital measures and fluid or imaging biomarkers reshape trial design. The PatSnap evidence set used here contains 523 matched trial records and 257 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07698496 | Intervention not normalized | Not Applicable; Not yet recruiting | Centre Hospitalier Universitaire de Grenoble | France | safety of the implant (2 years after surgery); Faisability of the SpeechBCI (1year after surgery to 2 years after surgery) | 2031-01-30 |
| ChiCTR2600127899 | Intervention not normalized | Not Applicable; Not yet recruiting | The First Affiliated Hospital of Nanchang University | China | Clinical diagnostic evaluation (baseline) | 2028-12-31 |
| JPRN-UMIN000062178 | Intervention not normalized | Not Applicable; 一般募集中/Open public recruiting | Tohoku University School of Medicine | Japan | 脳脊髄液中NfL濃度のトフェルセン投与開始時（ベースライン）から24週後の変化率（LS幾何平均比による評価）; Change of NfL concentration in CSF at Week 24 after Tofersen initiation from baseline (LS geometric mean ratio to baseline) | 2027-12-31 |
| NCT07688239 | Foralumab | Phase 2; Not yet recruiting | Tiziana Life Sciences Ltd. (Bermuda) | Geography not listed | Safety - Occurrence of serious and non-serious treatment emergent adverse events and clinically significant treatment emergent abnormalities. (12 weeks and 24 weeks); Tolerability - Percentage of participant that complete 12 or 24 weeks of study treatment. (12 and 24 Weeks) | 2027-07-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Expansion and Infusion of T-Regulatory Cells in Amyotrophic Lateral Sclerosis (Phase 1): the indexed record reports -; Number of Participants With Treatment-related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.0) & Medical Dictionary for Regulatory Activities (MedDRA). = 0 Participants; -.
- Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis (Phase 2): the indexed record reports Drug-related adverse events = 4.3 %; Drug-related adverse events = 20.0 %.
- Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis The PARADIGM Randomized Clinical Trial (Phase 2): the indexed record reports AE = 65.2 %; AE = 66.7 %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Foralumab (Phase 2; CD3ε). Company & Deal Intelligence records identify sponsor context for Centre Hospitalier Universitaire de Grenoble, The First Affiliated Hospital of Nanchang University, Tohoku University School of Medicine, Tiziana Life Sciences Ltd. (Bermuda) (TLSA). Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Validated biomarkers that bridge biological activity to meaningful function.
- Longer follow-up that distinguishes transient symptom change from altered disease trajectory.
- Decentralized and digital measures that reduce noise without increasing patient burden.
- Trials designed around genetically or biologically defined subgroups.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Amyotrophic Lateral Sclerosis has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
